Historical review from 2026-11-11. Current price and availability are unconfirmed; check the original marketplace.
Stacker is a verified iPhone app in the health & fitness niche that tracks peptide protocols, logging doses, reminders, and progress. The financials are remarkably clean: ~$428/mo profit on ~$437/mo revenue yields a 98% margin, which is exceptionally high and consistent with a low-overhead app-store product. At a $15,000 asking price the annual profit multiple comes to approximately 2.92x — a reasonable figure for a small mobile app. The business age is not disclosed and the revenue base is modest, so a buyer should validate the consistency of that revenue over time and understand the acquisition channel before committing.
The core software — a mobile peptide tracker with dose logging, reminders, and progress views — is straightforwardly reproducible by a solo founder using an AI coding assistant, SwiftUI or React Native, and a managed backend like Supabase. Out-of-pocket build cost would likely fall between $2,000–$6,000 including tools, App Store fees, and modest design assets. However, the case for buying rests on acquiring the existing verified revenue stream (~$428/mo profit), established App Store presence, and any organic ratings/reviews that lower user acquisition friction — assets that take time and iteration to earn, not just dollars. The verdict tips narrowly to buy because the 2.92x multiple is fair for verified recurring income, but the missing retention data and undisclosed business age meaningfully limit confidence. A buyer who can quickly confirm 6–12 months of stable revenue history and healthy churn will have strong justification for proceeding.
Cash estimate includes the AI tools, APIs and infrastructure needed for a solo founder to recreate the software. Build time is informational and lightly weighted. The verdict is driven mainly by customers, users, verified earnings, retention, distribution, brand, data and operating history.
Helps users build personalized peptide stacks, log doses, get reminders, and track protocol progress and results in one iPhone app.
Opens the original listing on TrustMRR
Get new listings with asking prices, monthly profit, deal scores, and key risks.
The best reviewed deals, concise and evidence-first. Unsubscribe anytime.
Preliminary screening based on marketplace and public data. Verify all financial, legal, technical, customer, and operational claims independently before making an acquisition decision. This is not financial or legal advice.